IL218037A0 - New benzimidazole derivatives and their use as fxr agonists - Google Patents

New benzimidazole derivatives and their use as fxr agonists

Info

Publication number
IL218037A0
IL218037A0 IL218037A IL21803712A IL218037A0 IL 218037 A0 IL218037 A0 IL 218037A0 IL 218037 A IL218037 A IL 218037A IL 21803712 A IL21803712 A IL 21803712A IL 218037 A0 IL218037 A0 IL 218037A0
Authority
IL
Israel
Prior art keywords
benzimidazole derivatives
fxr agonists
new benzimidazole
new
fxr
Prior art date
Application number
IL218037A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL218037A0 publication Critical patent/IL218037A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL218037A 2009-09-29 2012-02-09 New benzimidazole derivatives and their use as fxr agonists IL218037A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09171700 2009-09-29
PCT/EP2010/064217 WO2011039130A1 (en) 2009-09-29 2010-09-27 New benzimidazole derivatives and their use as fxr agonists

Publications (1)

Publication Number Publication Date
IL218037A0 true IL218037A0 (en) 2012-04-30

Family

ID=43033176

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218037A IL218037A0 (en) 2009-09-29 2012-02-09 New benzimidazole derivatives and their use as fxr agonists

Country Status (12)

Country Link
US (1) US8309581B2 (OSRAM)
EP (1) EP2483247A1 (OSRAM)
JP (1) JP5503007B2 (OSRAM)
KR (1) KR101477872B1 (OSRAM)
CN (1) CN102574812B (OSRAM)
AU (1) AU2010303146A1 (OSRAM)
BR (1) BR112012006986A2 (OSRAM)
CA (1) CA2772815A1 (OSRAM)
IL (1) IL218037A0 (OSRAM)
IN (1) IN2012DN01234A (OSRAM)
MX (1) MX2012002479A (OSRAM)
WO (1) WO2011039130A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3043865T (pt) 2013-09-11 2021-01-14 Univ Claude Bernard Lyon Métodos e composições farmacêuticas para o tratamento da infeção por vírus da hepatite b
CN108072684B (zh) * 2016-11-11 2020-06-16 中国科学院广州生物医药与健康研究院 法尼醇x受体的新配体及其筛选方法和应用
KR20190117632A (ko) 2017-02-21 2019-10-16 장피트 Ppar 효현제와 fxr 효현제의 병용
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
BRPI0713946A2 (pt) 2006-06-29 2012-12-04 Hoffmann La Roche compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr, e uso dos compostos
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
EP2188263B1 (en) * 2007-08-27 2012-06-27 F. Hoffmann-La Roche AG Benzimidazole derivatives used as fxr agonists
AU2008323017B2 (en) * 2007-11-15 2012-12-20 F. Hoffmann-La Roche Ag Methyl-benzimidazole derivatives
ES2407180T3 (es) * 2008-09-11 2013-06-12 F. Hoffmann-La Roche Ag Nuevos derivados de bencimidazol
AU2009304169A1 (en) * 2008-10-15 2010-04-22 F. Hoffmann-La Roche Ag New benzimidazole derivatives

Also Published As

Publication number Publication date
AU2010303146A1 (en) 2012-04-19
MX2012002479A (es) 2012-03-26
CA2772815A1 (en) 2011-04-07
KR20120063536A (ko) 2012-06-15
US20110077273A1 (en) 2011-03-31
HK1171746A1 (zh) 2013-04-05
CN102574812A (zh) 2012-07-11
JP5503007B2 (ja) 2014-05-28
US8309581B2 (en) 2012-11-13
WO2011039130A1 (en) 2011-04-07
EP2483247A1 (en) 2012-08-08
IN2012DN01234A (OSRAM) 2015-05-15
BR112012006986A2 (pt) 2016-04-12
KR101477872B1 (ko) 2014-12-30
JP2013505977A (ja) 2013-02-21
CN102574812B (zh) 2016-03-30

Similar Documents

Publication Publication Date Title
IL215251A0 (en) Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
IL200639A0 (en) Benzimidazole derivatives and methods of use thereof
ZA201206257B (en) N-(imidazopyrimidin-7yl)-heteroarylamide derivatives and their use as pde10a inhibitors
HRP20190016T1 (hr) Heterociklički spojevi i njihova upotreba
PL2504336T3 (pl) Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz
SMT201700158T1 (it) Derivati benzimidazolici come inibitori della chinasi pi3
IL214501A0 (en) Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2649060A4 (en) PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND THEIR SALTS
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
ZA201301120B (en) Heterocyclic compound and use thereof
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
PL2501693T3 (pl) Azaheterocykliczne akryloamidy i ich zastosowanie jako środków bakteriobójczych
SG173666A1 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
IL216802A0 (en) Histamine h3 inverse agonists and antagonists and methods of use thereof
IL205207A0 (en) Benzimidazole derivatives and their use as fxr agonists
SG10201609184PA (en) Compositions and methods for extended therapy with aminopyridines
IL209733A0 (en) New benzimidazole derivatives
IL208771A0 (en) Iminopyridine derivatives and use thereof
ZA201300036B (en) Banzamide derivatives and their use as hsp90 inhibitors
IL214406A0 (en) Derivatives of 6-(6-o-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
IL218037A0 (en) New benzimidazole derivatives and their use as fxr agonists
GB0902173D0 (en) Compounds and their use
IL211806A0 (en) New benzimidazole derivatives
IL214404A0 (en) Derivatives of 6-(6-nh-substituted-triazolopyridazine-sulfanyl)benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
IL217190A0 (en) Aalkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2a r agonists